nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—CYP1A1—kidney cancer	0.197	0.653	CbGaD
Propranolol—ABCB1—kidney cancer	0.105	0.347	CbGaD
Propranolol—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0373	0.0719	CbGbCtD
Propranolol—CYP3A7—Temsirolimus—kidney cancer	0.0373	0.0719	CbGbCtD
Propranolol—ORM1—Erlotinib—kidney cancer	0.031	0.0598	CbGbCtD
Propranolol—CYP3A5—Temsirolimus—kidney cancer	0.028	0.054	CbGbCtD
Propranolol—SLC22A2—Vinblastine—kidney cancer	0.0206	0.0397	CbGbCtD
Propranolol—ABCB1—Temsirolimus—kidney cancer	0.0182	0.0351	CbGbCtD
Propranolol—CYP1A1—Erlotinib—kidney cancer	0.0175	0.0337	CbGbCtD
Propranolol—CYP2D6—Temsirolimus—kidney cancer	0.0171	0.0331	CbGbCtD
Propranolol—CYP3A4—Everolimus—kidney cancer	0.0161	0.0312	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0128	0.0247	CbGbCtD
Propranolol—CYP3A7—Paclitaxel—kidney cancer	0.0128	0.0247	CbGbCtD
Propranolol—CYP3A7—Sorafenib—kidney cancer	0.0114	0.0219	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0114	0.0219	CbGbCtD
Propranolol—CYP3A7—Vincristine—kidney cancer	0.011	0.0213	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.011	0.0213	CbGbCtD
Propranolol—CYP1A2—Pazopanib—kidney cancer	0.0109	0.0211	CbGbCtD
Propranolol—CYP3A4—Temsirolimus—kidney cancer	0.0109	0.021	CbGbCtD
Propranolol—CYP3A5—Erlotinib—kidney cancer	0.0105	0.0202	CbGbCtD
Propranolol—CYP3A5—Paclitaxel—kidney cancer	0.00959	0.0185	CbGbCtD
Propranolol—ABCB1—Pazopanib—kidney cancer	0.00956	0.0185	CbGbCtD
Propranolol—CYP3A7—Sunitinib—kidney cancer	0.0092	0.0178	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0092	0.0178	CbGbCtD
Propranolol—CYP2D6—Pazopanib—kidney cancer	0.00901	0.0174	CbGbCtD
Propranolol—ABCB1—Dactinomycin—kidney cancer	0.00874	0.0169	CbGbCtD
Propranolol—CYP3A5—Sorafenib—kidney cancer	0.00852	0.0164	CbGbCtD
Propranolol—CYP3A5—Vincristine—kidney cancer	0.00827	0.016	CbGbCtD
Propranolol—CYP1A2—Erlotinib—kidney cancer	0.0078	0.0151	CbGbCtD
Propranolol—ABCB1—Gemcitabine—kidney cancer	0.00691	0.0133	CbGbCtD
Propranolol—CYP3A5—Sunitinib—kidney cancer	0.0069	0.0133	CbGbCtD
Propranolol—CYP2C19—Sorafenib—kidney cancer	0.00687	0.0133	CbGbCtD
Propranolol—ABCB1—Erlotinib—kidney cancer	0.00682	0.0132	CbGbCtD
Propranolol—CYP2D6—Erlotinib—kidney cancer	0.00643	0.0124	CbGbCtD
Propranolol—CYP1A2—Sorafenib—kidney cancer	0.00634	0.0122	CbGbCtD
Propranolol—ABCB1—Paclitaxel—kidney cancer	0.00624	0.0121	CbGbCtD
Propranolol—CYP3A4—Pazopanib—kidney cancer	0.00573	0.0111	CbGbCtD
Propranolol—ABCB1—Sorafenib—kidney cancer	0.00555	0.0107	CbGbCtD
Propranolol—ABCB1—Vinblastine—kidney cancer	0.00548	0.0106	CbGbCtD
Propranolol—ABCB1—Vincristine—kidney cancer	0.00538	0.0104	CbGbCtD
Propranolol—CYP2D6—Sorafenib—kidney cancer	0.00523	0.0101	CbGbCtD
Propranolol—CYP2D6—Vinblastine—kidney cancer	0.00516	0.00996	CbGbCtD
Propranolol—SLC22A2—nephron—kidney cancer	0.00465	0.205	CbGeAlD
Propranolol—ABCB1—Sunitinib—kidney cancer	0.00449	0.00867	CbGbCtD
Propranolol—CYP3A4—Erlotinib—kidney cancer	0.00409	0.00789	CbGbCtD
Propranolol—CYP3A4—Paclitaxel—kidney cancer	0.00374	0.00722	CbGbCtD
Propranolol—ABCB1—Doxorubicin—kidney cancer	0.00337	0.0065	CbGbCtD
Propranolol—CYP3A4—Sorafenib—kidney cancer	0.00332	0.00641	CbGbCtD
Propranolol—CYP3A4—Vinblastine—kidney cancer	0.00328	0.00633	CbGbCtD
Propranolol—CYP3A4—Vincristine—kidney cancer	0.00323	0.00623	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—kidney cancer	0.00317	0.00612	CbGbCtD
Propranolol—CYP3A4—Sunitinib—kidney cancer	0.00269	0.0052	CbGbCtD
Propranolol—CYP2C19—urine—kidney cancer	0.00203	0.0895	CbGeAlD
Propranolol—CYP3A4—Doxorubicin—kidney cancer	0.00202	0.00389	CbGbCtD
Propranolol—CYP1A2—urine—kidney cancer	0.00166	0.0731	CbGeAlD
Propranolol—CYP3A4—urine—kidney cancer	0.0012	0.0529	CbGeAlD
Propranolol—CYP2D6—urine—kidney cancer	0.00118	0.0521	CbGeAlD
Propranolol—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.00104	0.0459	CbGeAlD
Propranolol—SLC22A2—nephron tubule—kidney cancer	0.001	0.0442	CbGeAlD
Propranolol—SLC22A2—renal system—kidney cancer	0.000912	0.0402	CbGeAlD
Propranolol—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00089	0.0392	CbGeAlD
Propranolol—SLC22A2—kidney—kidney cancer	0.000882	0.0389	CbGeAlD
Propranolol—SLC22A2—cortex of kidney—kidney cancer	0.000859	0.0379	CbGeAlD
Propranolol—Carvedilol—HIF1A—kidney cancer	0.000752	0.333	CrCbGaD
Propranolol—ADRB1—cardiac atrium—kidney cancer	0.000556	0.0245	CbGeAlD
Propranolol—HTR1A—renal system—kidney cancer	0.000532	0.0235	CbGeAlD
Propranolol—CYP3A5—nephron tubule—kidney cancer	0.00043	0.019	CbGeAlD
Propranolol—CYP1A2—renal system—kidney cancer	0.000406	0.0179	CbGeAlD
Propranolol—CYP1A1—renal system—kidney cancer	0.0004	0.0176	CbGeAlD
Propranolol—CYP3A5—renal system—kidney cancer	0.000391	0.0173	CbGeAlD
Propranolol—CYP1A1—kidney—kidney cancer	0.000387	0.0171	CbGeAlD
Propranolol—CYP3A5—kidney—kidney cancer	0.000378	0.0167	CbGeAlD
Propranolol—CYP3A5—cortex of kidney—kidney cancer	0.000368	0.0162	CbGeAlD
Propranolol—CYP1A1—cardiac atrium—kidney cancer	0.000358	0.0158	CbGeAlD
Propranolol—Terbinafine—PTGS1—kidney cancer	0.000324	0.144	CrCbGaD
Propranolol—Carvedilol—VEGFA—kidney cancer	0.000303	0.134	CrCbGaD
Propranolol—CYP3A4—renal system—kidney cancer	0.000294	0.0129	CbGeAlD
Propranolol—CYP2D6—renal system—kidney cancer	0.000289	0.0127	CbGeAlD
Propranolol—CYP3A4—kidney—kidney cancer	0.000284	0.0125	CbGeAlD
Propranolol—CYP2D6—kidney—kidney cancer	0.000279	0.0123	CbGeAlD
Propranolol—ABCB1—nephron tubule—kidney cancer	0.000229	0.0101	CbGeAlD
Propranolol—ABCB1—renal system—kidney cancer	0.000208	0.00916	CbGeAlD
Propranolol—ABCB1—kidney—kidney cancer	0.000201	0.00886	CbGeAlD
Propranolol—ABCB1—cortex of kidney—kidney cancer	0.000196	0.00863	CbGeAlD
Propranolol—ABCB1—gonad—kidney cancer	0.000186	0.00822	CbGeAlD
Propranolol—Carvedilol—PTGS1—kidney cancer	0.00016	0.0709	CrCbGaD
Propranolol—Body temperature increased—Erlotinib—kidney cancer	0.000157	0.00125	CcSEcCtD
Propranolol—Visual impairment—Paclitaxel—kidney cancer	0.000156	0.00124	CcSEcCtD
Propranolol—Neutropenia—Capecitabine—kidney cancer	0.000156	0.00124	CcSEcCtD
Propranolol—Insomnia—Sunitinib—kidney cancer	0.000155	0.00124	CcSEcCtD
Propranolol—Decreased appetite—Sorafenib—kidney cancer	0.000155	0.00123	CcSEcCtD
Propranolol—Nausea—Pazopanib—kidney cancer	0.000155	0.00123	CcSEcCtD
Propranolol—Paraesthesia—Sunitinib—kidney cancer	0.000154	0.00123	CcSEcCtD
Propranolol—Convulsion—Vincristine—kidney cancer	0.000154	0.00123	CcSEcCtD
Propranolol—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000154	0.00123	CcSEcCtD
Propranolol—Fatigue—Sorafenib—kidney cancer	0.000154	0.00122	CcSEcCtD
Propranolol—Erythema multiforme—Paclitaxel—kidney cancer	0.000153	0.00122	CcSEcCtD
Propranolol—Dyspnoea—Sunitinib—kidney cancer	0.000153	0.00122	CcSEcCtD
Propranolol—Constipation—Sorafenib—kidney cancer	0.000153	0.00121	CcSEcCtD
Propranolol—Pain—Sorafenib—kidney cancer	0.000153	0.00121	CcSEcCtD
Propranolol—Hypersensitivity—Vinblastine—kidney cancer	0.000152	0.00121	CcSEcCtD
Propranolol—Hypersensitivity—Everolimus—kidney cancer	0.000151	0.00121	CcSEcCtD
Propranolol—Dyspepsia—Sunitinib—kidney cancer	0.000151	0.0012	CcSEcCtD
Propranolol—Cardiac disorder—Paclitaxel—kidney cancer	0.000151	0.0012	CcSEcCtD
Propranolol—Atenolol—ABCB1—kidney cancer	0.00015	0.0666	CrCbGaD
Propranolol—Decreased appetite—Sunitinib—kidney cancer	0.000149	0.00119	CcSEcCtD
Propranolol—Infestation—Capecitabine—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Infestation NOS—Capecitabine—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Asthenia—Vinblastine—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Fatigue—Sunitinib—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Depression—Capecitabine—kidney cancer	0.000148	0.00118	CcSEcCtD
Propranolol—Asthenia—Everolimus—kidney cancer	0.000147	0.00117	CcSEcCtD
Propranolol—Cough—Gemcitabine—kidney cancer	0.000147	0.00117	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000147	0.00117	CcSEcCtD
Propranolol—Pain—Sunitinib—kidney cancer	0.000147	0.00117	CcSEcCtD
Propranolol—Constipation—Sunitinib—kidney cancer	0.000147	0.00117	CcSEcCtD
Propranolol—Carvedilol—CYP1A1—kidney cancer	0.000146	0.0648	CrCbGaD
Propranolol—Gastrointestinal pain—Sorafenib—kidney cancer	0.000146	0.00116	CcSEcCtD
Propranolol—Anaphylactic shock—Vincristine—kidney cancer	0.000145	0.00116	CcSEcCtD
Propranolol—Infection—Vincristine—kidney cancer	0.000144	0.00115	CcSEcCtD
Propranolol—Alopecia—Paclitaxel—kidney cancer	0.000143	0.00114	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000143	0.00114	CcSEcCtD
Propranolol—Nervous system disorder—Vincristine—kidney cancer	0.000142	0.00113	CcSEcCtD
Propranolol—Asthenia—Erlotinib—kidney cancer	0.000142	0.00113	CcSEcCtD
Propranolol—Mental disorder—Paclitaxel—kidney cancer	0.000142	0.00113	CcSEcCtD
Propranolol—Urticaria—Sorafenib—kidney cancer	0.000142	0.00113	CcSEcCtD
Propranolol—Erythema—Paclitaxel—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Decreased appetite—Dactinomycin—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Diarrhoea—Vinblastine—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Body temperature increased—Sorafenib—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Abdominal pain—Sorafenib—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Diarrhoea—Everolimus—kidney cancer	0.000141	0.00112	CcSEcCtD
Propranolol—Gastrointestinal pain—Sunitinib—kidney cancer	0.00014	0.00112	CcSEcCtD
Propranolol—Fatigue—Dactinomycin—kidney cancer	0.00014	0.00112	CcSEcCtD
Propranolol—Pain—Dactinomycin—kidney cancer	0.000139	0.00111	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—kidney cancer	0.000139	0.0011	CcSEcCtD
Propranolol—Acebutolol—ABCB1—kidney cancer	0.000139	0.0615	CrCbGaD
Propranolol—Agranulocytosis—Capecitabine—kidney cancer	0.000138	0.0011	CcSEcCtD
Propranolol—Anaphylactic shock—Gemcitabine—kidney cancer	0.000138	0.0011	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—kidney cancer	0.000137	0.00109	CcSEcCtD
Propranolol—Infection—Gemcitabine—kidney cancer	0.000137	0.00109	CcSEcCtD
Propranolol—Dizziness—Vinblastine—kidney cancer	0.000136	0.00109	CcSEcCtD
Propranolol—Dizziness—Everolimus—kidney cancer	0.000136	0.00108	CcSEcCtD
Propranolol—Abdominal pain—Sunitinib—kidney cancer	0.000136	0.00108	CcSEcCtD
Propranolol—Body temperature increased—Sunitinib—kidney cancer	0.000136	0.00108	CcSEcCtD
Propranolol—Diarrhoea—Erlotinib—kidney cancer	0.000136	0.00108	CcSEcCtD
Propranolol—Bradycardia—Capecitabine—kidney cancer	0.000136	0.00108	CcSEcCtD
Propranolol—Nervous system disorder—Gemcitabine—kidney cancer	0.000135	0.00108	CcSEcCtD
Propranolol—Skin disorder—Gemcitabine—kidney cancer	0.000134	0.00106	CcSEcCtD
Propranolol—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000133	0.00106	CcSEcCtD
Propranolol—Pharyngitis—Capecitabine—kidney cancer	0.000132	0.00105	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000132	0.00105	CcSEcCtD
Propranolol—Hypersensitivity—Sorafenib—kidney cancer	0.000131	0.00105	CcSEcCtD
Propranolol—Insomnia—Vincristine—kidney cancer	0.000131	0.00105	CcSEcCtD
Propranolol—Vomiting—Vinblastine—kidney cancer	0.000131	0.00104	CcSEcCtD
Propranolol—Dizziness—Erlotinib—kidney cancer	0.000131	0.00104	CcSEcCtD
Propranolol—Vomiting—Everolimus—kidney cancer	0.000131	0.00104	CcSEcCtD
Propranolol—Paraesthesia—Vincristine—kidney cancer	0.00013	0.00104	CcSEcCtD
Propranolol—Agitation—Paclitaxel—kidney cancer	0.00013	0.00103	CcSEcCtD
Propranolol—Rash—Everolimus—kidney cancer	0.00013	0.00103	CcSEcCtD
Propranolol—Dermatitis—Everolimus—kidney cancer	0.000129	0.00103	CcSEcCtD
Propranolol—Purpura—Doxorubicin—kidney cancer	0.000129	0.00102	CcSEcCtD
Propranolol—Abdominal pain—Dactinomycin—kidney cancer	0.000128	0.00102	CcSEcCtD
Propranolol—Body temperature increased—Dactinomycin—kidney cancer	0.000128	0.00102	CcSEcCtD
Propranolol—Visual impairment—Capecitabine—kidney cancer	0.000128	0.00102	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000128	0.00102	CcSEcCtD
Propranolol—Asthenia—Sorafenib—kidney cancer	0.000128	0.00102	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—kidney cancer	0.000127	0.00101	CcSEcCtD
Propranolol—Vertigo—Paclitaxel—kidney cancer	0.000127	0.00101	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—kidney cancer	0.000127	0.00101	CcSEcCtD
Propranolol—Hypersensitivity—Sunitinib—kidney cancer	0.000126	0.00101	CcSEcCtD
Propranolol—Decreased appetite—Vincristine—kidney cancer	0.000126	0.001	CcSEcCtD
Propranolol—Vomiting—Erlotinib—kidney cancer	0.000126	0.001	CcSEcCtD
Propranolol—Erythema multiforme—Capecitabine—kidney cancer	0.000126	0.001	CcSEcCtD
Propranolol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000125	0.000998	CcSEcCtD
Propranolol—Fatigue—Vincristine—kidney cancer	0.000125	0.000996	CcSEcCtD
Propranolol—Rash—Erlotinib—kidney cancer	0.000125	0.000995	CcSEcCtD
Propranolol—Dermatitis—Erlotinib—kidney cancer	0.000125	0.000994	CcSEcCtD
Propranolol—Insomnia—Gemcitabine—kidney cancer	0.000125	0.000992	CcSEcCtD
Propranolol—Constipation—Vincristine—kidney cancer	0.000124	0.000988	CcSEcCtD
Propranolol—Pain—Vincristine—kidney cancer	0.000124	0.000988	CcSEcCtD
Propranolol—Paraesthesia—Gemcitabine—kidney cancer	0.000124	0.000984	CcSEcCtD
Propranolol—Cardiac disorder—Capecitabine—kidney cancer	0.000124	0.000984	CcSEcCtD
Propranolol—Cough—Paclitaxel—kidney cancer	0.000123	0.000981	CcSEcCtD
Propranolol—Asthenia—Sunitinib—kidney cancer	0.000123	0.00098	CcSEcCtD
Propranolol—Dyspnoea—Gemcitabine—kidney cancer	0.000123	0.000977	CcSEcCtD
Propranolol—Nausea—Vinblastine—kidney cancer	0.000123	0.000975	CcSEcCtD
Propranolol—Somnolence—Gemcitabine—kidney cancer	0.000122	0.000975	CcSEcCtD
Propranolol—Convulsion—Paclitaxel—kidney cancer	0.000122	0.000974	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—kidney cancer	0.000122	0.000972	CcSEcCtD
Propranolol—Nausea—Everolimus—kidney cancer	0.000122	0.000972	CcSEcCtD
Propranolol—Diarrhoea—Sorafenib—kidney cancer	0.000122	0.000971	CcSEcCtD
Propranolol—Decreased appetite—Gemcitabine—kidney cancer	0.00012	0.000953	CcSEcCtD
Propranolol—Hypersensitivity—Dactinomycin—kidney cancer	0.00012	0.000953	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000119	0.000951	CcSEcCtD
Propranolol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000119	0.000946	CcSEcCtD
Propranolol—Fatigue—Gemcitabine—kidney cancer	0.000119	0.000945	CcSEcCtD
Propranolol—Gastrointestinal pain—Vincristine—kidney cancer	0.000119	0.000945	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—kidney cancer	0.000118	0.000939	CcSEcCtD
Propranolol—Dizziness—Sorafenib—kidney cancer	0.000118	0.000939	CcSEcCtD
Propranolol—Constipation—Gemcitabine—kidney cancer	0.000118	0.000937	CcSEcCtD
Propranolol—Pain—Gemcitabine—kidney cancer	0.000118	0.000937	CcSEcCtD
Propranolol—Nausea—Erlotinib—kidney cancer	0.000118	0.000937	CcSEcCtD
Propranolol—Alopecia—Capecitabine—kidney cancer	0.000118	0.000937	CcSEcCtD
Propranolol—Mood swings—Doxorubicin—kidney cancer	0.000118	0.000936	CcSEcCtD
Propranolol—Diarrhoea—Sunitinib—kidney cancer	0.000117	0.000935	CcSEcCtD
Propranolol—Metoprolol—ABCB1—kidney cancer	0.000117	0.0519	CrCbGaD
Propranolol—Mental disorder—Capecitabine—kidney cancer	0.000117	0.000929	CcSEcCtD
Propranolol—Asthenia—Dactinomycin—kidney cancer	0.000117	0.000928	CcSEcCtD
Propranolol—Erythema—Capecitabine—kidney cancer	0.000116	0.000923	CcSEcCtD
Propranolol—Anaphylactic shock—Paclitaxel—kidney cancer	0.000115	0.000918	CcSEcCtD
Propranolol—Abdominal pain—Vincristine—kidney cancer	0.000115	0.000914	CcSEcCtD
Propranolol—Body temperature increased—Vincristine—kidney cancer	0.000115	0.000914	CcSEcCtD
Propranolol—Infection—Paclitaxel—kidney cancer	0.000115	0.000912	CcSEcCtD
Propranolol—Dizziness—Sunitinib—kidney cancer	0.000114	0.000903	CcSEcCtD
Propranolol—Vomiting—Sorafenib—kidney cancer	0.000113	0.000903	CcSEcCtD
Propranolol—Nervous system disorder—Paclitaxel—kidney cancer	0.000113	0.0009	CcSEcCtD
Propranolol—Rash—Sorafenib—kidney cancer	0.000112	0.000895	CcSEcCtD
Propranolol—Dermatitis—Sorafenib—kidney cancer	0.000112	0.000894	CcSEcCtD
Propranolol—Skin disorder—Paclitaxel—kidney cancer	0.000112	0.000892	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000112	0.00089	CcSEcCtD
Propranolol—Diarrhoea—Dactinomycin—kidney cancer	0.000111	0.000885	CcSEcCtD
Propranolol—Vomiting—Sunitinib—kidney cancer	0.000109	0.000869	CcSEcCtD
Propranolol—Body temperature increased—Gemcitabine—kidney cancer	0.000109	0.000867	CcSEcCtD
Propranolol—Rash—Sunitinib—kidney cancer	0.000108	0.000861	CcSEcCtD
Propranolol—Dermatitis—Sunitinib—kidney cancer	0.000108	0.000861	CcSEcCtD
Propranolol—Hypersensitivity—Vincristine—kidney cancer	0.000107	0.000851	CcSEcCtD
Propranolol—Nausea—Sorafenib—kidney cancer	0.000106	0.000843	CcSEcCtD
Propranolol—Insomnia—Paclitaxel—kidney cancer	0.000104	0.00083	CcSEcCtD
Propranolol—Vertigo—Capecitabine—kidney cancer	0.000104	0.000829	CcSEcCtD
Propranolol—Asthenia—Vincristine—kidney cancer	0.000104	0.000829	CcSEcCtD
Propranolol—Paraesthesia—Paclitaxel—kidney cancer	0.000104	0.000824	CcSEcCtD
Propranolol—Vomiting—Dactinomycin—kidney cancer	0.000103	0.000822	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—kidney cancer	0.000103	0.000821	CcSEcCtD
Propranolol—Dyspnoea—Paclitaxel—kidney cancer	0.000103	0.000818	CcSEcCtD
Propranolol—Somnolence—Paclitaxel—kidney cancer	0.000103	0.000816	CcSEcCtD
Propranolol—Rash—Dactinomycin—kidney cancer	0.000102	0.000816	CcSEcCtD
Propranolol—Nausea—Sunitinib—kidney cancer	0.000102	0.000812	CcSEcCtD
Propranolol—Dyspepsia—Paclitaxel—kidney cancer	0.000102	0.000808	CcSEcCtD
Propranolol—Cough—Capecitabine—kidney cancer	0.000101	0.000805	CcSEcCtD
Propranolol—Neutropenia—Doxorubicin—kidney cancer	0.0001	0.000798	CcSEcCtD
Propranolol—Decreased appetite—Paclitaxel—kidney cancer	0.0001	0.000798	CcSEcCtD
Propranolol—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.96e-05	0.000792	CcSEcCtD
Propranolol—Fatigue—Paclitaxel—kidney cancer	9.94e-05	0.000791	CcSEcCtD
Propranolol—Diarrhoea—Vincristine—kidney cancer	9.93e-05	0.000791	CcSEcCtD
Propranolol—Asthenia—Gemcitabine—kidney cancer	9.88e-05	0.000787	CcSEcCtD
Propranolol—Pain—Paclitaxel—kidney cancer	9.86e-05	0.000785	CcSEcCtD
Propranolol—Constipation—Paclitaxel—kidney cancer	9.86e-05	0.000785	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.8e-05	0.00078	CcSEcCtD
Propranolol—Nausea—Dactinomycin—kidney cancer	9.65e-05	0.000768	CcSEcCtD
Propranolol—Dizziness—Vincristine—kidney cancer	9.6e-05	0.000764	CcSEcCtD
Propranolol—Infestation—Doxorubicin—kidney cancer	9.57e-05	0.000761	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—kidney cancer	9.57e-05	0.000761	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	9.48e-05	0.000755	CcSEcCtD
Propranolol—Gastrointestinal pain—Paclitaxel—kidney cancer	9.43e-05	0.000751	CcSEcCtD
Propranolol—Diarrhoea—Gemcitabine—kidney cancer	9.42e-05	0.00075	CcSEcCtD
Propranolol—Infection—Capecitabine—kidney cancer	9.4e-05	0.000748	CcSEcCtD
Propranolol—Nervous system disorder—Capecitabine—kidney cancer	9.28e-05	0.000739	CcSEcCtD
Propranolol—Vomiting—Vincristine—kidney cancer	9.23e-05	0.000735	CcSEcCtD
Propranolol—Skin disorder—Capecitabine—kidney cancer	9.19e-05	0.000732	CcSEcCtD
Propranolol—Urticaria—Paclitaxel—kidney cancer	9.16e-05	0.000729	CcSEcCtD
Propranolol—Rash—Vincristine—kidney cancer	9.16e-05	0.000729	CcSEcCtD
Propranolol—Dermatitis—Vincristine—kidney cancer	9.15e-05	0.000728	CcSEcCtD
Propranolol—Abdominal pain—Paclitaxel—kidney cancer	9.12e-05	0.000726	CcSEcCtD
Propranolol—Body temperature increased—Paclitaxel—kidney cancer	9.12e-05	0.000726	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—kidney cancer	8.93e-05	0.00071	CcSEcCtD
Propranolol—Vomiting—Gemcitabine—kidney cancer	8.76e-05	0.000697	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—kidney cancer	8.74e-05	0.000696	CcSEcCtD
Propranolol—Rash—Gemcitabine—kidney cancer	8.69e-05	0.000691	CcSEcCtD
Propranolol—Dermatitis—Gemcitabine—kidney cancer	8.68e-05	0.000691	CcSEcCtD
Propranolol—Propafenone—ABCB1—kidney cancer	8.63e-05	0.0383	CrCbGaD
Propranolol—Nausea—Vincristine—kidney cancer	8.62e-05	0.000686	CcSEcCtD
Propranolol—Insomnia—Capecitabine—kidney cancer	8.56e-05	0.000681	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—kidney cancer	8.52e-05	0.000678	CcSEcCtD
Propranolol—Paraesthesia—Capecitabine—kidney cancer	8.5e-05	0.000676	CcSEcCtD
Propranolol—Hypersensitivity—Paclitaxel—kidney cancer	8.5e-05	0.000676	CcSEcCtD
Propranolol—Dyspnoea—Capecitabine—kidney cancer	8.44e-05	0.000672	CcSEcCtD
Propranolol—Dyspepsia—Capecitabine—kidney cancer	8.33e-05	0.000663	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—kidney cancer	8.28e-05	0.000659	CcSEcCtD
Propranolol—Asthenia—Paclitaxel—kidney cancer	8.27e-05	0.000659	CcSEcCtD
Propranolol—Decreased appetite—Capecitabine—kidney cancer	8.23e-05	0.000655	CcSEcCtD
Propranolol—Nausea—Gemcitabine—kidney cancer	8.18e-05	0.000651	CcSEcCtD
Propranolol—Gastrointestinal disorder—Capecitabine—kidney cancer	8.17e-05	0.00065	CcSEcCtD
Propranolol—Fatigue—Capecitabine—kidney cancer	8.16e-05	0.000649	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—kidney cancer	8.12e-05	0.000646	CcSEcCtD
Propranolol—Pain—Capecitabine—kidney cancer	8.09e-05	0.000644	CcSEcCtD
Propranolol—Constipation—Capecitabine—kidney cancer	8.09e-05	0.000644	CcSEcCtD
Propranolol—Cardiac disorder—Doxorubicin—kidney cancer	7.97e-05	0.000634	CcSEcCtD
Propranolol—Diarrhoea—Paclitaxel—kidney cancer	7.89e-05	0.000628	CcSEcCtD
Propranolol—Carvedilol—ABCB1—kidney cancer	7.77e-05	0.0345	CrCbGaD
Propranolol—Gastrointestinal pain—Capecitabine—kidney cancer	7.74e-05	0.000616	CcSEcCtD
Propranolol—Dizziness—Paclitaxel—kidney cancer	7.63e-05	0.000607	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—kidney cancer	7.59e-05	0.000604	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—kidney cancer	7.52e-05	0.000599	CcSEcCtD
Propranolol—Urticaria—Capecitabine—kidney cancer	7.52e-05	0.000598	CcSEcCtD
Propranolol—Abdominal pain—Capecitabine—kidney cancer	7.48e-05	0.000595	CcSEcCtD
Propranolol—Body temperature increased—Capecitabine—kidney cancer	7.48e-05	0.000595	CcSEcCtD
Propranolol—Erythema—Doxorubicin—kidney cancer	7.48e-05	0.000595	CcSEcCtD
Propranolol—Vomiting—Paclitaxel—kidney cancer	7.33e-05	0.000584	CcSEcCtD
Propranolol—Rash—Paclitaxel—kidney cancer	7.27e-05	0.000579	CcSEcCtD
Propranolol—Dermatitis—Paclitaxel—kidney cancer	7.26e-05	0.000578	CcSEcCtD
Propranolol—Hypersensitivity—Capecitabine—kidney cancer	6.97e-05	0.000555	CcSEcCtD
Propranolol—Agitation—Doxorubicin—kidney cancer	6.87e-05	0.000547	CcSEcCtD
Propranolol—Nausea—Paclitaxel—kidney cancer	6.85e-05	0.000545	CcSEcCtD
Propranolol—Asthenia—Capecitabine—kidney cancer	6.79e-05	0.00054	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—kidney cancer	6.72e-05	0.000534	CcSEcCtD
Propranolol—Cough—Doxorubicin—kidney cancer	6.52e-05	0.000519	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—kidney cancer	6.48e-05	0.000515	CcSEcCtD
Propranolol—Diarrhoea—Capecitabine—kidney cancer	6.48e-05	0.000515	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.32e-05	0.000503	CcSEcCtD
Propranolol—Dizziness—Capecitabine—kidney cancer	6.26e-05	0.000498	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—kidney cancer	6.1e-05	0.000486	CcSEcCtD
Propranolol—Infection—Doxorubicin—kidney cancer	6.06e-05	0.000482	CcSEcCtD
Propranolol—Vomiting—Capecitabine—kidney cancer	6.02e-05	0.000479	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—kidney cancer	5.98e-05	0.000476	CcSEcCtD
Propranolol—Rash—Capecitabine—kidney cancer	5.97e-05	0.000475	CcSEcCtD
Propranolol—Dermatitis—Capecitabine—kidney cancer	5.96e-05	0.000474	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—kidney cancer	5.93e-05	0.000472	CcSEcCtD
Propranolol—Nausea—Capecitabine—kidney cancer	5.62e-05	0.000447	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—kidney cancer	5.52e-05	0.000439	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—kidney cancer	5.48e-05	0.000436	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—kidney cancer	5.44e-05	0.000433	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—kidney cancer	5.42e-05	0.000432	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—kidney cancer	5.37e-05	0.000427	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—kidney cancer	5.3e-05	0.000422	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.27e-05	0.000419	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—kidney cancer	5.26e-05	0.000419	CcSEcCtD
Propranolol—Constipation—Doxorubicin—kidney cancer	5.22e-05	0.000415	CcSEcCtD
Propranolol—Pain—Doxorubicin—kidney cancer	5.22e-05	0.000415	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—kidney cancer	4.99e-05	0.000397	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—kidney cancer	4.85e-05	0.000386	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—kidney cancer	4.82e-05	0.000384	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—kidney cancer	4.82e-05	0.000384	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—kidney cancer	4.49e-05	0.000358	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—kidney cancer	4.38e-05	0.000348	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—kidney cancer	4.17e-05	0.000332	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—kidney cancer	4.03e-05	0.000321	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—kidney cancer	3.88e-05	0.000309	CcSEcCtD
Propranolol—Rash—Doxorubicin—kidney cancer	3.85e-05	0.000306	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—kidney cancer	3.84e-05	0.000306	CcSEcCtD
Propranolol—Nausea—Doxorubicin—kidney cancer	3.62e-05	0.000288	CcSEcCtD
Propranolol—ADRB1—GPCR downstream signaling—IL2—kidney cancer	5.07e-06	0.000175	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—ERBB2—kidney cancer	5.06e-06	0.000174	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—RAF1—kidney cancer	5.02e-06	0.000173	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—LDHB—kidney cancer	5.01e-06	0.000173	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MTOR—kidney cancer	4.99e-06	0.000172	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—IL2—kidney cancer	4.96e-06	0.000171	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SCARB1—kidney cancer	4.93e-06	0.00017	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—RAF1—kidney cancer	4.91e-06	0.000169	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS1—kidney cancer	4.88e-06	0.000168	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KIT—kidney cancer	4.85e-06	0.000167	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—APC—kidney cancer	4.85e-06	0.000167	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—IL2—kidney cancer	4.85e-06	0.000167	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SCARB1—kidney cancer	4.81e-06	0.000166	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTT1—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ACHE—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CRABP1—kidney cancer	4.79e-06	0.000165	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PSMD7—kidney cancer	4.78e-06	0.000165	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS1—kidney cancer	4.76e-06	0.000164	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CDKN1B—kidney cancer	4.68e-06	0.000162	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PSMD7—kidney cancer	4.67e-06	0.000161	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GSTP1—kidney cancer	4.67e-06	0.000161	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—MAPK3—kidney cancer	4.65e-06	0.00016	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—POMC—kidney cancer	4.62e-06	0.000159	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL2—kidney cancer	4.61e-06	0.000159	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL2—kidney cancer	4.58e-06	0.000158	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—BRAF—kidney cancer	4.56e-06	0.000157	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—BCHE—kidney cancer	4.54e-06	0.000156	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SCARB1—kidney cancer	4.53e-06	0.000156	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL2—kidney cancer	4.5e-06	0.000155	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS1—kidney cancer	4.49e-06	0.000155	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SLC5A5—kidney cancer	4.48e-06	0.000155	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.47e-06	0.000154	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCND1—kidney cancer	4.47e-06	0.000154	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—JUN—kidney cancer	4.46e-06	0.000154	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ITPR2—kidney cancer	4.45e-06	0.000153	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—BCHE—kidney cancer	4.43e-06	0.000153	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CTNNB1—kidney cancer	4.42e-06	0.000153	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—MAPK1—kidney cancer	4.42e-06	0.000153	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ABCB1—kidney cancer	4.42e-06	0.000152	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GSTP1—kidney cancer	4.41e-06	0.000152	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL2—kidney cancer	4.4e-06	0.000152	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PSMD7—kidney cancer	4.4e-06	0.000152	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HIF1A—kidney cancer	4.39e-06	0.000151	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TSC2—kidney cancer	4.38e-06	0.000151	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SLC5A5—kidney cancer	4.37e-06	0.000151	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CA9—kidney cancer	4.34e-06	0.00015	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—SLC2A1—kidney cancer	4.33e-06	0.000149	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PTEN—kidney cancer	4.31e-06	0.000149	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HIF1A—kidney cancer	4.29e-06	0.000148	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GSTM1—kidney cancer	4.29e-06	0.000148	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TSC2—kidney cancer	4.28e-06	0.000148	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—PIK3CA—kidney cancer	4.23e-06	0.000146	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—SLC2A1—kidney cancer	4.22e-06	0.000146	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.2e-06	0.000145	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HIF1A—kidney cancer	4.2e-06	0.000145	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KDR—kidney cancer	4.2e-06	0.000145	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—POMC—kidney cancer	4.19e-06	0.000145	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—POMC—kidney cancer	4.19e-06	0.000144	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TSC2—kidney cancer	4.19e-06	0.000144	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—KRAS—kidney cancer	4.18e-06	0.000144	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ABCB1—kidney cancer	4.17e-06	0.000144	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—BCHE—kidney cancer	4.17e-06	0.000144	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.12e-06	0.000142	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KDR—kidney cancer	4.11e-06	0.000142	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.1e-06	0.000141	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP1A1—kidney cancer	4.07e-06	0.00014	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTT1—kidney cancer	4.06e-06	0.00014	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ACHE—kidney cancer	4.06e-06	0.00014	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GSTM1—kidney cancer	4.05e-06	0.00014	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.03e-06	0.000139	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KDR—kidney cancer	4.01e-06	0.000138	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.98e-06	0.000137	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—VEGFA—kidney cancer	3.9e-06	0.000134	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KIT—kidney cancer	3.87e-06	0.000133	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—APC—kidney cancer	3.87e-06	0.000133	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SCARB1—kidney cancer	3.84e-06	0.000132	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—PIK3CA—kidney cancer	3.84e-06	0.000132	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—RAF1—kidney cancer	3.81e-06	0.000131	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS1—kidney cancer	3.8e-06	0.000131	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—RELA—kidney cancer	3.79e-06	0.000131	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KIT—kidney cancer	3.78e-06	0.00013	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—APC—kidney cancer	3.78e-06	0.00013	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ERBB2—kidney cancer	3.77e-06	0.00013	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PSMD7—kidney cancer	3.73e-06	0.000129	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MTOR—kidney cancer	3.72e-06	0.000128	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	3.7e-06	0.000128	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KIT—kidney cancer	3.7e-06	0.000128	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—APC—kidney cancer	3.7e-06	0.000128	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CRABP1—kidney cancer	3.69e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MAPK3—kidney cancer	3.68e-06	0.000127	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—POMC—kidney cancer	3.68e-06	0.000127	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.66e-06	0.000126	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—BRAF—kidney cancer	3.63e-06	0.000125	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	3.62e-06	0.000125	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTP1—kidney cancer	3.61e-06	0.000125	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—POMC—kidney cancer	3.6e-06	0.000124	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MYC—kidney cancer	3.58e-06	0.000124	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—BRAF—kidney cancer	3.55e-06	0.000123	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK3—kidney cancer	3.54e-06	0.000122	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—BCHE—kidney cancer	3.53e-06	0.000122	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	3.52e-06	0.000122	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTP1—kidney cancer	3.52e-06	0.000122	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—POMC—kidney cancer	3.52e-06	0.000121	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MAPK1—kidney cancer	3.51e-06	0.000121	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.49e-06	0.00012	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1B—kidney cancer	3.49e-06	0.00012	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—BRAF—kidney cancer	3.48e-06	0.00012	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	3.45e-06	0.000119	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ITPR2—kidney cancer	3.43e-06	0.000118	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ABCB1—kidney cancer	3.42e-06	0.000118	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL2—kidney cancer	3.42e-06	0.000118	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.37e-06	0.000116	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK1—kidney cancer	3.37e-06	0.000116	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	3.37e-06	0.000116	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—kidney cancer	3.35e-06	0.000115	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—kidney cancer	3.34e-06	0.000115	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—kidney cancer	3.33e-06	0.000115	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—kidney cancer	3.33e-06	0.000115	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—JUN—kidney cancer	3.32e-06	0.000115	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTP1—kidney cancer	3.32e-06	0.000115	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTM1—kidney cancer	3.32e-06	0.000114	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—kidney cancer	3.31e-06	0.000114	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CTNNB1—kidney cancer	3.3e-06	0.000114	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	3.29e-06	0.000114	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.27e-06	0.000113	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—kidney cancer	3.25e-06	0.000112	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTM1—kidney cancer	3.24e-06	0.000112	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.22e-06	0.000111	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—kidney cancer	3.21e-06	0.000111	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—kidney cancer	3.18e-06	0.00011	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.16e-06	0.000109	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.14e-06	0.000108	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCB1—kidney cancer	3.14e-06	0.000108	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTT1—kidney cancer	3.13e-06	0.000108	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ACHE—kidney cancer	3.13e-06	0.000108	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP1A1—kidney cancer	3.07e-06	0.000106	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	3.06e-06	0.000105	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTM1—kidney cancer	3.05e-06	0.000105	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—kidney cancer	3.04e-06	0.000105	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—RAF1—kidney cancer	3.03e-06	0.000105	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—POMC—kidney cancer	3.03e-06	0.000105	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—RELA—kidney cancer	3.02e-06	0.000104	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ERBB2—kidney cancer	3e-06	0.000104	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	2.99e-06	0.000103	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—RAF1—kidney cancer	2.97e-06	0.000102	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SCARB1—kidney cancer	2.96e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MTOR—kidney cancer	2.96e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—RELA—kidney cancer	2.95e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—kidney cancer	2.94e-06	0.000102	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ERBB2—kidney cancer	2.94e-06	0.000101	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS1—kidney cancer	2.93e-06	0.000101	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	2.92e-06	0.000101	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—kidney cancer	2.92e-06	0.000101	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—kidney cancer	2.91e-06	0.0001	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—kidney cancer	2.9e-06	0.0001	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—RAF1—kidney cancer	2.9e-06	0.0001	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MTOR—kidney cancer	2.9e-06	0.0001	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.89e-06	9.98e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—RELA—kidney cancer	2.89e-06	9.97e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PSMD7—kidney cancer	2.88e-06	9.93e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ERBB2—kidney cancer	2.87e-06	9.91e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—POMC—kidney cancer	2.86e-06	9.88e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.85e-06	9.84e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MTOR—kidney cancer	2.83e-06	9.78e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTP1—kidney cancer	2.81e-06	9.7e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	2.78e-06	9.59e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK3—kidney cancer	2.75e-06	9.47e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—BCHE—kidney cancer	2.73e-06	9.41e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL2—kidney cancer	2.72e-06	9.39e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	2.72e-06	9.38e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.69e-06	9.29e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—kidney cancer	2.67e-06	9.21e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCB1—kidney cancer	2.66e-06	9.18e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL2—kidney cancer	2.66e-06	9.18e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	2.66e-06	9.17e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—kidney cancer	2.65e-06	9.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—JUN—kidney cancer	2.65e-06	9.13e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	2.63e-06	9.06e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK1—kidney cancer	2.61e-06	9.01e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL2—kidney cancer	2.6e-06	8.98e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.6e-06	8.98e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—kidney cancer	2.59e-06	8.95e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—JUN—kidney cancer	2.59e-06	8.93e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTM1—kidney cancer	2.58e-06	8.91e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.58e-06	8.91e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	2.57e-06	8.86e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—kidney cancer	2.56e-06	8.83e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—kidney cancer	2.54e-06	8.75e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—JUN—kidney cancer	2.53e-06	8.73e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	2.51e-06	8.67e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—kidney cancer	2.5e-06	8.64e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—kidney cancer	2.47e-06	8.51e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.45e-06	8.45e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—kidney cancer	2.45e-06	8.45e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—kidney cancer	2.42e-06	8.34e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—POMC—kidney cancer	2.34e-06	8.09e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—kidney cancer	2.31e-06	7.98e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—POMC—kidney cancer	2.29e-06	7.89e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—kidney cancer	2.28e-06	7.88e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	2.27e-06	7.82e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—kidney cancer	2.26e-06	7.8e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—kidney cancer	2.21e-06	7.63e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—kidney cancer	2.19e-06	7.57e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK3—kidney cancer	2.19e-06	7.55e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTP1—kidney cancer	2.17e-06	7.49e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—POMC—kidney cancer	2.16e-06	7.44e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK3—kidney cancer	2.14e-06	7.38e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—kidney cancer	2.13e-06	7.34e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—kidney cancer	2.11e-06	7.28e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK3—kidney cancer	2.09e-06	7.22e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK1—kidney cancer	2.08e-06	7.18e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—kidney cancer	2.08e-06	7.18e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.06e-06	7.1e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—kidney cancer	2.06e-06	7.09e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCB1—kidney cancer	2.05e-06	7.09e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK1—kidney cancer	2.04e-06	7.02e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—kidney cancer	2.03e-06	7.02e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.01e-06	6.94e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTM1—kidney cancer	1.99e-06	6.88e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—kidney cancer	1.99e-06	6.87e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK1—kidney cancer	1.99e-06	6.87e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—kidney cancer	1.97e-06	6.78e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—kidney cancer	1.92e-06	6.63e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.89e-06	6.52e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—kidney cancer	1.88e-06	6.49e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—kidney cancer	1.87e-06	6.45e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—POMC—kidney cancer	1.83e-06	6.3e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—kidney cancer	1.82e-06	6.3e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	1.81e-06	6.23e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	1.77e-06	6.09e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—kidney cancer	1.75e-06	6.03e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	1.73e-06	5.96e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—kidney cancer	1.72e-06	5.93e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—kidney cancer	1.71e-06	5.9e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—kidney cancer	1.67e-06	5.76e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—kidney cancer	1.63e-06	5.63e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—kidney cancer	1.59e-06	5.49e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—kidney cancer	1.5e-06	5.17e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.49e-06	5.13e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—kidney cancer	1.46e-06	5.03e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—POMC—kidney cancer	1.41e-06	4.86e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.41e-06	4.85e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—kidney cancer	1.27e-06	4.38e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.15e-06	3.97e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—kidney cancer	1.12e-06	3.88e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—kidney cancer	1.12e-06	3.87e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.06e-06	3.65e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—kidney cancer	9.8e-07	3.38e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—kidney cancer	8.96e-07	3.09e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.92e-07	2.39e-05	CbGpPWpGaD
